<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940667</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALOS-301</org_study_id>
    <nct_id>NCT00940667</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension</brief_title>
  <official_title>A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan
      and amlodipine alone in patients with essential hypertension inadequately controlled on
      amlodipine monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean sitting diastolic blood pressure</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting diastolic blood pressure</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>amlodipine/losartan 5/50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Losartan</intervention_name>
    <description>amlodipine/losartan 5/50mg q.d.</description>
    <arm_group_label>amlodipine/losartan 5/50mg</arm_group_label>
    <other_name>Amosartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>amlodipine 5mg q.d.</description>
    <arm_group_label>amlodipine 5mg</arm_group_label>
    <other_name>Amodpine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age

          -  Essential hypertensive patients whose blood pressure is not controlled before the
             study (sit DBP ≥ 90 mmHg for drug-treated patient, sit DBP ≥ 95 mmHg for drug-naïve
             patient)

          -  Non-responder to 4 weeks treatment of amlodipine 5 mg monotherapy (sit DBP ≥ 90mmHg)

        Exclusion Criteria:

          -  mean sit SBP ≥ 200 mmHg or mean sit DBP ≥ 120 mmHg at screening

          -  mean sit SBP ≥ 180 mmHg or mean sit DBP ≥ 120 mmHg after 4 weeks of amlodipine 5 mg
             treatment

          -  has a history of hypersensitivity to dihydropyridines or angiotensin II receptor
             blockers

          -  Secondary hypertensive patient or suspected to be

          -  Uncontrolled diabetes mellitus patients

          -  Severe heart disease or severe neurovascular disease

          -  Known as severe or malignant retinopathy

          -  Patients showed clinically significant hematological finding, patients with renal
             diseases (serum creatinine), patients with hepatic disease (ALT or AST)

          -  History of malignancy tumor

          -  History of autoimmune disease

          -  History of alcohol or drug abuse

          -  Positive to pregnancy test, nursing mother, has an intention on pregnancy

          -  Considered by investigator as not appropriate to participate in the clinical study
             with othe reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Yun Cho, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>13 sites in Korea</name>
      <address>
        <city>Seoul, Busan, etc.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amlodipine</keyword>
  <keyword>Losartan</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

